Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor and Methotrexate GVHD Prophylaxis, with or without ATG, in HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies Undergoing Reduced-Intensity Conditioning: A CIBMTR Analysis of 5,950 Participants | Synapse
March 3, 2026
Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor and Methotrexate GVHD Prophylaxis, with or without ATG, in HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies Undergoing Reduced-Intensity Conditioning: A CIBMTR Analysis of 5,950 Participants
Key Points
Cyclophosphamide shows potential advantages in preventing graft-versus-host disease (GVHD) in adults with hematologic malignancies.
In a cohort of 5,950 participants, outcomes favor cyclophosphamide compared to conventional therapies.
Analysis based on donor types and conditioning regimens highlights specific population benefits.
These findings may indicate a shift in standard approaches for GVHD prophylaxis in hematopoietic cell transplantation.